Clear cell renal cell carcinomas (ccRCC) highly express carbonic anhydrase IX, targeted by girentuximab due to the overexpression of hypoxia-inducible factor-1 alpha (HIF-1α) as these tumours are fast growing and highly hypoxic. The gene discussed is HIF1A; the disease is neoplasm.